KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.
The DOI matches its Crossref record.
Abstract
3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This approval was based in part on data from cohort A of the phase 2 KEYNOTE-164 (NCT02460198) study of pts with MSI-H CRC after ≥2 prior lines of therapy including fluoropyrimidine, oxaliplatin, and irinotecan. In addition, in Cohort B of KEYNOTE-164, we evaluated the activity of pembrolizumab in pts with metastatic MSI-H CRC treated with ≥1 prior line of therapy. Methods: KEYNOTE-164 cohort B enrolled pts with metastatic CRC, MSI-H status confirmed locally by IHC or PCR, and ≥1 prior line of therapy (fluoropyrimidine, oxaliplatin, irinotecan, or anti VEGF/EGFR). Eligible pts received pembrolizumab 200 mg Q3W for 2 years or until progression, unacceptable toxicity, or withdrawal of consent. Tumor response was assessed Q9W per RECIST v1.1 by independent review. The primary endpoint was ORR. Secondary endpoints included DOR, PFS, OS, and safety. Results: Of 63 pts enrolled, median age (range) was 59 years (23-83), and 52% were male. Pts had a median of 2 prior therapies, and 94% had ≥1 prior therapy for advanced disease. As of Sep 12, 2017, median (range) duration of follow-up was 12.6 months (0.1-15.4). ORR was 32% (95% CI, 21-45) with 2 CRs and 18 PRs. Median DOR was not reached (NR); 95% of responses were ongoing with DOR ≥6 mo in 75% of responders. Median PFS was 4.1 month (95% CI, 2.1-NR) with a 12-month PFS rate of 41%. Median OS was NR with a 12-month OS rate of 76%. Forty (64%) pts had any grade treatment-related AEs, most commonly (≥10%) fatigue (18%), hypothyroidism (16%), and hyperthyroidism (11%); 7 (11%) pts had grade 3-4 treatment-related AEs of anemia, thrombocytopenia, diarrhea, pneumatosis intestinalis, arthritis, syncope, pneumonitis, and vasculitis (n = 1 each). There were no treatment-related deaths. Twenty (32%) pts had any grade immune-mediated AEs; 2 (3%) pts had grade 3-4 immune-mediated AEs of colitis and pneumonitis (n = 1 each). Conclusions: Pembrolizumab provided durable antitumor activity with a manageable safety profile in patients with MSI-H CRC that progressed after ≥1 prior line of therapy. Clinical trial information: NCT02460198.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Bell, H. N., Rebernick, R. J., Goyert, J., Singhal, R., Kuljanin, M., Kerk, S. A., Huang, W., Das, N. K., Andren, A., Solanki, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.001 · Cited by 296
Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., Ng, M., Chen, L. T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy498 · Cited by 289
Self-citationMorse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
“11%, respectively), in previously treated patients with MSI-H/dMMR mCRC [24].”
Background
Metadata
- Authors
- Le, D. T., Kavan, P., Kim, T. W., Burge, M. E., Van Cutsem, E., Hara, H., Boland, P. M., Van Laethem, J.-L., Geva, R., Taniguchi, H., Crocenzi, T. S., Sharma, M., Atreya, C. E., Diaz, L. A., Liang, L. W., Marinello, P., Dai, T., & O'Neil, B. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-20
- Volume
- 36
- Issue
- 15_suppl
- Pages
- 3514-3514
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2891243575
- Cited by
- 85
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3514
- The paper
- Le, D. T., Kavan, P., Kim, T. W., Burge, M. E., Van Cutsem, E., Hara, H., Boland, P. M., Van Laethem, J.-L., Geva, R., Taniguchi, H., Crocenzi, T. S., Sharma, M., Atreya, C. E., Diaz, L. A., Liang, L. W., Marinello, P., Dai, T., & O'Neil, B. H. (2018). KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.